

Decisions on new HML products and restrictions changes

PHARMAC has made decisions for the following products, with the changes being effective **from 5 July 2013**:

Defibrotide

- The restriction applying to defibrotide injections will be amended as follows (deletions in strikethrough, additions in bold):

Restricted – Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of **chemotherapy or regimen-related toxicities** ~~after allogeneic stem cell transplantation.~~

Edrophonium chloride

- Another presentation of edrophonium chloride – inj 10 mg per ml, 15 ml vial, will be listed subject to the same restriction that currently applies to edrophonium chloride 10 mg per ml, 1 ml ampoule.

Oestriol

- There will be a correction to the naming of the medicine oestradiol tab 2mg, which should be oestriol tab 2mg in the Other Oestrogen Preparations subsection of the Hormone Preparations therapeutic group.

Atovaquone with proguanil hydrochloride

- A paediatric presentation of atovaquone with proguanil hydrochloride will be listed – atovaquone with proguanil hydrochloride tab 62.5 mg with proguanil hydrochloride 25 mg.
- This new presentation will be subject to the same restrictions as the atovaquone with proguanil hydrochloride tab 250 mg with proguanil hydrochloride 100mg presentation.

Amendment to the restriction applying to immunisations

- The restrictions currently applying to the following vaccines will be amended as follows (additions in bold):

Vaccines:

Diphtheria and tetanus vaccine

Haemophilus influenzae type b vaccine

Pneumococcal conjugate (pcv13) vaccine

Pneumococcal (ppv23) polysaccharide vaccine

Diphtheria, tetanus, pertussis, polio, hepatitis b and haemophilus influenzae type b vaccine

Restriction change:

For revaccination **of children** following immunosuppression

Sodium chloride nasal spray

- The listing of sodium chloride nasal spray will be amended as follows (additions in bold, deletions in strikethrough):

SODIUM CHLORIDE

Aqueous nasal spray ~~6.5~~ **7.4** mg per ml

Cabergoline

- The restrictions applying to cabergoline will be amended as follows (additions in bold):

CABERGOLINE

Tab 0.5 mg

Restricted

Either:

1. **Inhibition of lactation**
2. Patient has pathological hyperprolactinemia
3. Patient has acromegaly

Bupivacaine

- A larger bag size of bupivacaine hydrochloride will be listed – inj 1.25 mg per ml, 500 ml bag.